Core Viewpoint - SHP2 inhibitors are emerging as a significant target for cancer treatment, with rapid development in the industry, particularly in China, which is becoming a notable player in the global market [1][6][9]. Industry Overview - SHP2, a protein tyrosine phosphatase, plays a crucial role in regulating various cellular functions, including growth, differentiation, and oncogenic transformation [2][6]. - The global market for SHP2 inhibitors is projected to start existing from 2027, reaching approximately $329 million by 2029, and is expected to grow to $4.821 billion by 2033 [1][7][9]. Market Size - The Chinese SHP2 inhibitor market is anticipated to grow to $206 million by 2029 and reach $784 million by 2033 [9][10]. Industry Chain - The SHP2 inhibitor industry chain includes upstream components such as protein reagents, specific antibodies, small molecule building blocks, testing kits, and experimental models; midstream involves drug research and production; downstream consists of large oncology specialty hospitals and comprehensive hospital oncology departments [11][12]. Development Environment - Recent policies in China have been implemented to encourage the pharmaceutical industry, particularly in the development and production of innovative drugs, including cancer therapies, by shortening clinical application and approval times [13][14]. Competitive Landscape - Major companies in the SHP2 inhibitor space include Innovent Biologics, CanSino Biologics, Junshi Biosciences, and others, with significant progress in developing SHP2 inhibitors, although no drugs have yet been approved for commercialization [15][16]. - Notable companies include: - **QinHao Pharmaceutical**: Focused on developing innovative candidates targeting the RAS signaling pathway, with its lead candidate GH21 in Phase II clinical trials [15][16]. - **Nuocheng Jianhua**: Known for its BTK inhibitor, it is also developing a new SHP2 inhibitor, ICP-189, in collaboration with ArriVent Biopharma [16][17]. Future Outlook - The SHP2 inhibitor sector is one of the hottest areas in pharmaceutical research, with significant advancements in the development of allosteric inhibitors and ongoing clinical trials showing promising results [17][18].

Core Viewpoint - Tianyu Co., Ltd. focuses on serving large multinational pharmaceutical companies and original research drug companies, aiming to deepen its "customer first" strategic goal [1] Group 1: Business Strategy - The company has provided active pharmaceutical ingredients (APIs) for 8 original research drug varieties and aims to add 1-2 new commercialized APIs annually with original research drug companies [1] - The company seeks to strengthen existing partnerships with original research clients while expanding its customer base to enhance its competitive advantage in APIs [1] Group 2: Strategic Partnerships - Tianyu has established long-term stable strategic partnerships with internationally renowned pharmaceutical companies such as Novartis, Sanofi, and Daiichi Sankyo [1] - The scope of cooperation has expanded from sartans APIs to non-sartan APIs, off-patent drugs, and innovative drug CDMO projects, indicating an increase in both depth and breadth of collaboration [1]

Core Insights - Major multinational pharmaceutical companies are showing robust revenue growth and increased sales of core products as they release their 2025 performance results [1][2] - Johnson & Johnson leads with nearly $94.2 billion in revenue, while Eli Lilly's weight loss drug, tirzepatide, shows a remarkable 45% year-over-year growth [1][2] Group 1: Revenue Performance - Johnson & Johnson reported total revenue of $94.193 billion for 2025, marking a 6% increase year-over-year [2] - Roche follows with revenue of $74.428 billion, while Eli Lilly, Merck, Pfizer, and AbbVie each exceeded $60 billion in revenue [2] - Eli Lilly's revenue reached $65.179 billion, a 44.7% increase, driven by strong sales of tirzepatide, which generated $36.5 billion [6] Group 2: Product Performance - Johnson & Johnson's innovative pharmaceuticals and medical technology segments both achieved revenue growth, with $60.401 billion and $33.792 billion respectively, both up by approximately 6% [2] - The CAR-T therapy, ciltacabtagene autoleucel, contributed significantly to Johnson & Johnson's growth, with revenue of $1.887 billion, a 95.9% increase [2] - Eli Lilly's tirzepatide sales reached $36.5 billion, with the weight loss version generating $13.542 billion, a 175% increase [6] Group 3: Market Trends and Challenges - The pharmaceutical industry faces a looming "patent cliff," with an estimated $236 billion in revenue at risk from patent expirations between 2025 and 2030 [8] - Companies are increasingly engaging in business development transactions to replenish their R&D pipelines, with Chinese innovative pharmaceutical companies gaining prominence [8][9] - In 2025, Chinese companies achieved record-breaking business development deals, totaling $135.655 billion, with significant collaborations involving major multinational firms [9]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical industry [3] Core Insights - The commercialization of ADC (Antibody-Drug Conjugates) is accelerating, with 20 ADC drugs approved globally, and 6 of them have been in the "billion-dollar club" for two consecutive years [30][31] - The report highlights the increasing competition in the ADC sector, with approximately 60 ADC drugs currently in clinical phase 3 and application stages [30] - Domestic innovative pharmaceutical companies are adopting various strategies for ADC capacity layout, with companies like Rongchang Biopharma transitioning from outsourcing to in-house production, while others like Kelong Biotechnology are building their own production bases [31][32] Summary by Sections Market Review - The pharmaceutical index rose by 0.14% this week, outperforming the CSI 300 index by 1.47 percentage points, ranking 15th in industry performance [10] - Year-to-date, the pharmaceutical index has increased by 3.28%, also outperforming the CSI 300 index by 2.99 percentage points, ranking 23rd [10] Individual Stock Performance - In the A-share market, 255 out of 479 pharmaceutical stocks rose, with the top five performers being Guangshengtang (+29.83%), Haixiang Pharmaceutical (+18.64%), and Meidixi (+18.04%) [20] - In the Hong Kong market, 38 out of 116 pharmaceutical stocks rose, with the top performers including Yiteng Jiahe (+14%) and Kedi-B (+9.96%) [24] Industry News and Policies - The newly revised "Regulations on the Implementation of the Drug Administration Law" supports segmented contract manufacturing and commercial-scale drug sales, providing a foundation for ADC commercialization cooperation [32] - Notable industry developments include Novartis's application for Ianalumab in China and Johnson & Johnson's approval of Daratumumab injection for multiple myeloma treatment [27][28] Weekly Insights - The ADC commercialization battle has begun, with a significant increase in demand for ADC production capacity, leading to a supply-demand imbalance [30] - Major CXO companies are expanding ADC production capacity, with companies like WuXi AppTec acquiring East Yao Pharmaceutical to meet rising orders [31]

Core Insights - Longhua Technology (联化科技) is positioned as a leading player in the agricultural and pharmaceutical CDMO sectors, with significant achievements in small nucleic acid CDMO and potential in functional chemicals [1][2] Business Overview - Longhua Technology has established a collaborative development framework across four core industrial segments: agricultural protection, pharmaceuticals, functional chemicals, and equipment & engineering services [2] - The agricultural protection segment generated revenue of 1.702 billion yuan in the first half of 2025, with a gross margin increase of 9.48% year-on-year [2] - The pharmaceutical segment, focusing on APIs and intermediates, achieved revenue of 1.018 billion yuan in the first half of 2025, reflecting a year-on-year growth of 42.80% [2] Small Nucleic Acid CDMO - The company is leveraging small nucleic acid CDMO to tap into new growth opportunities, with advantages over traditional small molecule and antibody drugs, including broader target selection and higher success rates [3] - Since 2022, the market for small nucleic acid drugs has seen significant activity, with 32 transactions totaling 29.022 billion USD in 2025, indicating strong commercial value [3] - Longhua Technology has developed scalable production processes for modified nucleotides and has established a high-efficiency delivery system for nucleic acid drugs, enhancing its competitive edge [3] Functional Chemicals and Market Potential - The functional chemicals segment reported revenue of 0.265 billion yuan in the first half of 2025, marking a year-on-year doubling [4] - The company is focusing on lithium battery materials, including lithium hexafluorophosphate and LiFSI, with ongoing product development in various testing phases [4] - The National Development and Reform Commission's new storage action plan aims for over 1.8 million kilowatts by 2027, which is expected to drive significant market demand in the energy storage sector [4] Financial Performance - For the first three quarters of 2025, Longhua Technology reported total revenue of 4.718 billion yuan, an increase of 8.25% year-on-year, and a net profit of 316 million yuan, surging by 871.65% [1] - The projected net profit for 2025 is estimated to be between 350 million and 420 million yuan, representing a year-on-year growth of 239.35% to 307.22% [4]

证券研究报告·行业跟踪周报·医药生物 医药生物行业跟踪周报 分子胶海外风起，国内管线蓄势破局 2026 年 02 月 09 日 增持（维持） [Table_Tag] [Table_Summary] 投资要点 证券分析师 朱国广 执业证书：S0600520070004 zhugg@dwzq.com.cn 行业走势 -8% -4% 0% 4% 8% 12% 16% 20% 24% 2025/2/10 2025/6/10 2025/10/8 2026/2/5 医药生物 沪深300 相关研究 《降息等多因素支持科研上游持续复 苏，重点推荐皓元医药、奥浦迈等》 2026-02-01 《mRNA 疫苗龙头释放积极临床数据 信号，建议关注悦康药业、康希诺等》 2026-01-26 东吴证券研究所 1 / 45 请务必阅读正文之后的免责声明部分 ◼ 本周、年初至今 A 股医药指数涨幅分别为 0.14%、3.28%，相对沪深 300 的超额收益分别为 1.41%、0.85%；本周、年初至今恒生生物科技指数涨 跌幅分别为-1.31%、7.34%，相对于恒生科技指数跑赢 5.20%、10.41%； 本周中药（2.56%）、医疗服务 ...

Group 1 - WeChat's public relations director emphasized user experience and announced changes to the red envelope sharing mechanism to address user complaints about the Yuanbao app [4] - Vivo confirmed the internal project for a Vlog camera aimed at competing with DJI's Pocket series, expected to be released in 2026 [4] - JD's Qixian Xiaochu became Beijing's first officially registered online meal service for the elderly, providing a new dining option for seniors [7] Group 2 - Novo Nordisk reported that sales of its flagship product, semaglutide, reached approximately 250.84 billion yuan in 2022, with a year-on-year growth of over 10% [8] - The U.S. stock market showed mixed results, with AMD experiencing a significant drop of over 17%, marking its worst single-day performance since 2017 [5] - Panasonic announced potential layoffs could expand to 12,000 employees as part of its restructuring efforts [10] Group 3 - The National Healthcare Security Administration of China is conducting collective interviews with mental health insurance institutions to strengthen management and combat misuse of insurance funds [9] - Multiple small and medium-sized banks in China have announced increases in deposit rates ahead of the Spring Festival, while some banks have opted to lower rates [11][12] - Walmart's market capitalization surpassed $1 trillion, with its stock price increasing over 24% in the past year [12] Group 4 - HP's CEO Enrique Lores will take over as CEO of PayPal, aiming to enhance execution efficiency and advance existing strategic initiatives [13] - The 3D printing industry in China is experiencing growth, with several listed companies reporting increased performance and expanding applications across various sectors [13] - Tesla is reportedly still working on integrating Apple's CarPlay into its vehicles, despite previous speculation that the project had been abandoned [15]

Group 1 - Novo Nordisk's semaglutide sales reached 250.84 billion yuan in 2025, with a year-on-year growth of over 10% [5] - The sales breakdown includes 127.09 billion Danish kroner for Ozempic, 79.11 billion for Wegovy, and 22.09 billion for oral semaglutide [5] - In China, the total sales for all three semaglutide products amounted to 6.81 billion Danish kroner (approximately 7.49 billion yuan) [5] Group 2 - The Hong Kong High Court rejected Xu Jiayin's appeal regarding the appointment of a receiver and ordered him to pay 1.2 million HKD in legal fees by February 20 [6] - The National Healthcare Security Administration is conducting collective interviews with mental health insurance institutions to strengthen management and combat misuse of insurance funds [6][7] Group 3 - Panasonic's CFO announced potential layoffs could expand to 12,000 employees, following a previous plan to cut 10,000 jobs globally [8] - Multiple small and medium-sized banks have announced increases in deposit rates ahead of the Spring Festival, while some banks have opted to lower rates [8] Group 4 - Walmart's market capitalization surpassed 1 trillion USD, with a stock price increase of over 24% in the past year [10] - PayPal announced that Enrique Lores will take over as CEO on March 1, aiming to enhance execution efficiency and advance strategic initiatives [11] Group 5 - AMD reported a fourth-quarter net profit of 2.52 billion USD, with a year-on-year growth of 42% and revenue of 10.27 billion USD, exceeding market expectations [23] - Alphabet's fourth-quarter net profit was 34.455 billion USD, a 29.8% increase year-on-year, with total revenue of 113.83 billion USD [21]

Policy Developments - Shanghai aims to vigorously cultivate and develop future industries such as brain-computer interfaces and fourth-generation semiconductors, as stated in the government work report presented at the Shanghai Municipal People's Congress [1] Drug and Medical Device Approvals - Novartis announced that its innovative biological drug Cosentyx (secukinumab) has received approval from the National Medical Products Administration in China for a new indication to treat active non-radiographic axial spondyloarthritis in adults who have had an inadequate response to non-steroidal anti-inflammatory drugs [2] - Hualan Biological announced that its recombinant Exendin-4-Fc fusion protein injection (HL08) has received clinical trial approval for use in adult patients with obesity or overweight, expanding its indications beyond type 2 diabetes [3] - Bibet's BEBT-701, a globally first AGT/PCSK9 dual-target siRNA drug, has received approval for clinical trials to treat mild to moderate hypertension combined with elevated low-density lipoprotein cholesterol [4] - Zhifei Biological's mRNA vaccine for shingles has received clinical trial approval from the National Medical Products Administration [5] Financial Data - Yaokang Biological reported a total revenue of 793 million yuan for 2025, a year-on-year increase of 15.49%, and a net profit of 144 million yuan, reflecting a growth of 31.49% [6] Industry Developments - Jichuan Pharmaceutical's wholly-owned subsidiary has signed an exclusive commercialization rights agreement for the Inusimab injection, paying an authorization fee of 80 million yuan [7][8] - Insilico Medicine announced it received a milestone payment of 39 million HKD from Menarini after the MEN2501 project completed its first patient dosing in Phase I clinical trials [9] - WuXi Biologics has signed a licensing and research service agreement with Vertex Pharmaceuticals for an innovative trispecific T cell engager, which will be used to treat B cell-mediated autoimmune diseases [10]

Core Insights - The JPMorgan Global Healthcare Conference serves as a significant platform for the biopharmaceutical industry, influencing capital flows and industry dynamics for the year ahead [1] - This year's conference highlighted the increasing presence of Chinese biotech companies, marking a shift from being mere spectators to key players in the global market [2][3] Group 1: Chinese Biotech Companies - Seven Chinese companies, including WuXi AppTec and BeiGene, presented on the main stage, with an additional 17 companies showcasing in the Asia-Pacific session [2] - The transformation of Chinese companies from the periphery to the center of the conference reflects their substantial innovation value, evidenced by numerous licensing deals announced during the event [3] Group 2: Licensing Deals and Collaborations - Notable licensing agreements included a $650 million upfront payment from AbbVie to Rongchang Biopharma for the global rights to its PD-1/VEGF dual-specific antibody, with a total potential deal value of up to $5.6 billion [3] - Other significant collaborations involved Zhongsheng Peptide and Sai Shen Pharmaceutical partnering with Novartis, with the latter's deal valued at approximately $1.665 billion [3] Group 3: MNCs and Market Dynamics - The cautious approach of multinational corporations (MNCs) towards acquisitions is driven by the impending "patent cliff," with over $320 billion in market potential products set to lose patent protection in the next decade [3][5] - MNCs are increasingly favoring "asset-based acquisitions" over full company buyouts, allowing them to efficiently acquire core assets without the burdens of integrating entire companies [4] Group 4: AI in Drug Development - AI's integration into drug development emerged as a central theme, with Eli Lilly and NVIDIA announcing a partnership to establish a $1 billion AI innovation lab aimed at addressing long-standing challenges in the pharmaceutical industry [5][6] - The acquisition of Modella AI by AstraZeneca further emphasizes the growing importance of AI in enhancing drug discovery and clinical development processes [6] Group 5: Future Outlook - The 2026 JPM conference is expected to reflect a new paradigm where Chinese innovation becomes essential, and AI evolves from a supportive tool to a foundational infrastructure in drug development [8][9]